Could reduce the likelihood of developing acute COVID-19^1,2 and may

PREVENT

long COVID^3,4

REDUCE

its impact on underlying
conditions^5-9

LIMIT

incidence and outbreaks in
closed settings²

DID YOU KNOW?

Long COVID affected almost 1 in 3 people after SARS-CoV-2 infection in the U.S. in a meta-analysis of 19 studies¹⁰

Explore the impact of
Long COVID

Patients with COVID-19 may experience exacerbation of pre-existing underlying conditions^5-9,11-13

Uncover COVID-19's impact on underlying conditions

Up to 47% of household contacts experienced a secondary SARS-CoV-2 infection during the Omicron era^14-16

Learn how households drive transmission of COVID-19

Explore the impact of COVID-19 on patients

Adults with multiple comorbidities

Immuno-compromised patients

Individuals in long-term care

Older
Adults

People who live with high-risk patients

Healthcare
workers

Individuals with long COVID who become reinfected

Adults with
multiple comorbidities^17,18

Adults with multiple comorbidities had greater inpatient and outpatient health care resource utilization than those with one condition or who were immunocompromised*^,18

Learn more about the comorbid conditions associated with severe outcomes for COVID-19

*Study conducted during the period of Omicron XBB dominance ≥40% (January 2023 to June 2023).

COVID-19, coronavirus disease 2019.

Immunocompromised
patients¹⁹

COVID‑19 hospitalization, ICU admission, and mortality were ~6‑fold higher for broadly defined IC group and ~11‑fold higher for stringently defined IC group versus the unexposed*^,19

Learn more about how immunocompromised patients are at increased risk for severe outcomes

*Data from English patients collected in studies found between March 2020 and
March 2022. A broad IC definition included all conditions/treatments generally considered immunocompromising; and a stringent definition was based on criteria aligned with U.K. pandemic guidelines.

COVID-19, coronavirus disease 2019; IC, immunocompromised; ICU, intensive care unit; U.K., United Kingdom.

Individuals in
long-term care^20,21

In the U.S., COVID-19 surge patterns in LTCF residents mirrored the general population, and were associated with increased hospitalizations and mortality*^,20

Explore the current COVID-19 cases and hospitalization rates in LTCF here

*Analysis included data from 43 U.S.-based studies published after January 1, 2022 during Omicron predominance.

COVID-19, coronavirus disease 2019; LTCF, long-term care facility; U.S., United States.

Older adults^17,22

88% of in-hospital deaths during COVID-19‒associated hospitalizations occurred in U.S. adults aged ≥65 years*^,22

*Data was collected between January and August 2023.

COVID-19, coronavirus disease 2019; U.S., United States.

People who live with
high-risk patients^14,15

Households are a major site for SARS-CoV-2 transmission, with up to 47% secondary attack rates in the U.S. during the Omicron era*^,14,15

*Baker JM, et al study was conducted between November 2021 and February 2022 in the U.S.¹⁴ Madewell ZJ, et al is a systematic literature review of 135 articles published between June 2021 and March 2022.¹⁵

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; U.S., United States.

Healthcare workers²³

The attack rates of the Omicron variant among healthcare workers in one study ranged between 16% (BA.4/5) and 37% (BA.1/2)*^,23

*This study was conducted in the U.K. between October 2020 and August 2022.

COVID-19, coronavirus disease 2019; U.K., United Kingdom.

Individuals with long COVID
who become reinfected²⁴

Individuals with long COVID may experience higher reinfection rates and worsening symptoms post-Omicron than those without long COVID*^,24

*Data was collected in Wuhan, China between January 2022 and April 2023.

COVID, coronavirus disease; COVID-19, coronavirus disease 2019.

Early intervention after exposure may help reduce incidence of COVID-19^1,2

The Omicron variant is highly transmissible,^14–16 and exposure can happen in various places,^25–28 starting with home¹⁴

Choose a location to explore viral spread

Long-term
care facilities

Workplaces

Cruise ships

Hospitals

Social gatherings

Correctional
Institutions

Schools and dormitories

Airport and airplanes

Households settings

Shared spaces mean shared risk:^33,34
Even asymptomatic patients may spread infection³⁵ and early intervention after exposure may help protect our communities^1,2

For those who have been exposed to someone infected with COVID-19, early intervention after exposure may help to reduce

Risk of developing COVID-19^1,2

Viral load^1,2

Duration of symptoms¹

Risk of long COVID by preventing acute infection^1,3,4

Reach out to your MSL to learn more about COVID-19 and the potential of early intervention

Abbreviations: COVID, coronavirus disease; COVID-19, coronavirus disease 2019; IC, immunocompromised; ICU, intensive care unit; LTCF, long-term care facility; MSL, medical science liaison; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; U.K., United Kingdom; U.S., United States.

References: 1. O'Brien MP, et al. N Engl J Med. 2021;385(13):1184-1195; 2. Cohen MS, et al. JAMA. 2021;326(1):46–55; 3. Al-Aly Z, et al. Nat Med. 2024;30(8):2148–2164; 4. Al-Aly Z, et al. Science. 2024;383(6685):830–832; 5. Kubota T, et al. Clin Neurol Neurosurg. 2021;200:106349; 6. Sakibuzzaman M, et al. Cureus. 2022;14(9):e29297; 7. Conway SE, et al. Mult Scler Relat Disord. 2022;63:103946; 8. Kwok WC, et al. Sci Rep. 2024;14(1):13881; 9. Kwok WC, et al. Respirology. 2024;29(3):209-216; 10. Peng Y-L, et al. Cancers (Basel). 2024;16(2):304; 11. Kwok WC, et al. Respir Res. 2023;24(1):53; 12. Di Iorio M, et al. Semin Arthritis Rheum. 2022;55:152025; 13. Marsters CM, et al. Brain. 2024;147(7):2542-2551; 14. Baker JM, et al. PLoS One. 2025;20(1):e0313680; 15. Madewell ZJ, et al. JAMA Netw Open. 2022;5(4):e229317; 16. Sumsuzzman DM, et al. BMC Infect Dis. 2025;25:215; 17. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html. Accessed December 24, 2025; 18. Ernst F, et al. Poster presented at the European Respiratory Society Congress. September 7–11, 2024, Vienna, Austria (PA1522). 19. Evans RA, et al. Lancet Reg Health Eur. 2023;35:100747; 20. Gravenstein S, et al. Poster Presented at American Society of Consultant Pharmacists Annual Meeting & Exhibition. October 23-26, 2025. San Diego, CA; 21. Centers for Disease Control and Prevention. https://www.cdc.gov/nhsn/ltc/ltc-report-overview.html. Accessed December 24, 2025; 22. Taylor CA, et al. MMWR Morb Mortal Wkly Rep. 2023;72(40):1089–1094; 23. Monk EJM, et al. J Infect. 2025;90(2):106393; 24. Zhang H, et al. Lancet Respir Med. 2024;12(1):55–66; 25. 2025 ASCP Research & Education Poster Abstracts: Presented at the ASCP Annual Meeting & Exhibition Town and Country Resort, San Diego, California October 23-26, 2025. Sr Care Pharm. 2025 Dec 1;40(12):505-525; 26. Francis MR, et al. J Infect Dis. 2024;230(4):e824–e836; 27. Heinsohn T, et al. PLoS Med. 2022;19(12):e1003913; 28. Hatfield KM, et al. JAMA Netw Open. 2023;6(8):e2329441; 29. Hayward AC, et al. Wellcome Open Res. 2020;5:54; 30. Zhao D, et al. Int J Environ Res Public Health. 2024;21(6):654; 31. Rosca EC, et al. Trop Med Infect Dis. 2022;7(10):290; 32. Marquez N, et al. JAMA. 2021;326(18):1865–1867; 33. Moon J, et al. Environ Res. 2021;202:111679; 34. Peng Z, et al. Environ Sci Technol. 2022;56(2):1125–1137; 35. Johansson MA, et al. JAMA Netw Open. 2021;4(1):e2035057.

Could reduce the likelihood of developing acute COVID-191,2 and may